Skip to Main Content

INFORMATION FOR

    News from around Yale and the World

    • A suspected case of pneumonic plague is raising fears of an outbreak. Should you be worried?

      “What we do worry about the most is pneumonic plague,” says Richard Martinello, a professor of infectious disease and pediatrics at the Yale School of Medicine. “People who are sick with pneumonia due to Y. pestis can produce droplets that contain the bacteria, and we know that they could be highly contagious and readily spread the Y. pestis to other people.”

      Source: Scientific American Online (with Richard Martinello, MD)
      Read more
    • Turning Research into Action: YIGH's BEGIN Network Helps Shape Connecticut Law

      Health scientists and clinical care providers have long recognized that health is shaped by far more than healthcare alone. Air and water pollution, transportation, housing, economic opportunity, and other environmental and social factors all influence health, yet efforts to address these issues often occur in isolation. Work led by Yale policy and health researchers, developed with significant contributions from Suzi Ruhl, JD, MPH, co-leader of the Yale Biological Embedding, Global Research & Intervention Network (BEGIN) at YIGH, has now helped shape Connecticut legislation that brings scientists, policymakers, and communities to the same table on these complex challenges.

      Read more
    • Making Access to Innovation Integral to our Research

      Dr. James Shepherd, infectious diseases specialist at the Yale School of Medicine, attended a two-day meeting hosted by Johns Hopkins University and Unitaid in Washington, DC, on "Reimagining Academia's Role in Closing Access Gaps Across the R&D-to-Delivery Continuum." The meeting brought together academic researchers, NGOs, the Gates Foundation, NIH, and WHO to discuss building equity of access into global health research from the start, addressing a long-standing pattern in which academic trials in LMICs generate the evidence, while funders control resulting IP, licensing, and pricing, often limiting access to the very treatments and diagnostics these trials help develop.

      Read more
    Get RSS Feed